AccuMetab™ Human CYP2D6 Enzyme, Catalytically Active

CAT#: ITS-0426-YL4
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2D6 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Despite its low relative abundance in the liver, CYP2D6 is responsible for the Phase I metabolism of over 25% of clinical therapeutics, particularly CNS and cardiovascular agents. It is subject to extreme genetic polymorphism, making it an essential focus for pharmacogenetic profiling and predicting inter-individual clearance variability.
Key Features
Proprietary E. coli expression; High and low reductase ratio options; Essential for basic amine and CNS drug profiling; Baseline model for extreme genetic polymorphism
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Drug-Drug Interactions (DDI); Toxicology
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry